Cardinal Health expands network of radiopharmaceutical manufacturing and distribution
Will manage ProVision's cyclotron in Tennessee
The Nuclear Pharmacy Business of Cardinal operates the largest network of “radiopharmacies” and production capacity in the US, with roughly 100 pharmacies compounding and dispensing molecular imaging biomarkers that are used in clinical research and diagnosis and care for patients suffering cancer, neurological disorders and heart disease. (Cardinal has an additional 60 pharmacies that only dispense the agents.) Now, in an agreement with ProVision Healthcare, the company will manage ProVision’s cyclotron in Knoxville, TN.
A cyclotron, which is itself used in therapy, can produce imaging agents for a technique called positron emission tomography (PET). Cardinal pharmacies compound, package and dispense patient-specific PET agents with radiopharmaceuticals produced by the cyclotron.
ProVision’s cyclotron is part of the East Tennessee Health Center, which includes diagnostic imaging, breast care and wellness, oncology and cardiology services. Cardinal will also make the facility available to support the development of new PET imaging agents.
LogiPharma Unpacked: Highlights, Key Insights, and the Road to 2025
October 16th 2024In this special post-show episode, we sit down with Ryan Portela, Head of Production for LogiPharma, to reflect on the highlights and key takeaways from this year’s event. From attendee feedback to the most impactful sessions, Ryan shares insider insights and discusses how the momentum from 2024 will continue to shape the future of pharma supply chains. Plus, get a sneak peek into the exciting plans for LogiPharma's 20th Anniversary in 2025.
Reimagining Closed-Loop Marketing Strategies for Pharma Companies
November 21st 2024The pharmaceutical industry is evolving, and so are the strategies needed to connect with healthcare professionals. Closed-loop marketing (CLM) has become essential in delivering personalized, data-driven engagement that resonates with physicians and improves key outcomes, such as enhancing patient care, increasing
Maximize Pharma’s Potential with AI-Ready Data for Commercial Excellence
November 21st 2024As the pharmaceutical industry embraces the power of AI, having data that’s large, diverse, and well-structured is critical for driving innovation and improving outcomes. Ensuring your data is AI-ready and can be used with more advanced solutions enables your teams to make informed strategic decisions, predict trends, enhance customer engagements and drive overall strategy.
